The identification of clinical candidate SB-480848: A potent inhibitor of lipoprotein-associated phospholipase A2

Bioorganic and Medicinal Chemistry Letters

Volumn 13, Issue 6, 2003, Pages 1067-1070

  Blackie, Josie A ^a   Bloomer, Jackie C ^a   Brown, Murray J B ^a   Cheng, Hung Yuan ^a   Hammond, Beverley ^a   Hickey, Deirdre M B ^a   Ife, Robert J ^a   Leach, Colin A ^a   Lewis, V Ann ^a   Macphee, Colin H ^a   Milliner, Kevin J ^a   Moores, Kitty E ^a   Pinto, Ivan L ^a   Smith, Stephen A ^a   Stansfield, Ian G ^a   Stanway, Steven J ^a   Taylor, Maxine A ^a   Theobald, Colin J ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIPHENYL DERIVATIVE; DARAPLADIB; FUNCTIONAL GROUP; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 INHIBITOR; PYRIMIDINONE DERIVATIVE; RECOMBINANT PROTEIN; SB 435495; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CHEMICAL MODIFICATION; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; CYTOCHROME P-450 CYP2D6; ENZYME INHIBITORS; HUMANS; KINETICS; PHOSPHOLIPASES A; PYRIMIDINONES; RABBITS; RECOMBINANT PROTEINS;

EID: 0037463766     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(03)00058-1     Document Type: Article

References (12)

1. Libby P., Ridker P.M., Maseri A. Circulation. 105:2002;1135.
2. Suckling K.E., Macphee C.H. Exp. Opin. Ther. Targets. 6:2002;309.
3. Macphee C.H. Curr. Opin. Pharmacology. 1:2001;121. and references therein.
4. Packard C.J., O'Reilly D.St.J., Caslake M.J., McMahon A.D., Ford I., Cooney J., Macphee C.H., Suckling K.E., Krishna M., Wilkinson F.E., Rumley A., Lowe G.D.O. N. Engl. J. Med. 343:2000;1148.
5. Blackie J.A., Bloomer J.C., Brown M.J.B., Cheng H.-Y., Elliott R.L., Hammond B., Hickey D.M.B., Ife R.J., Leach C.A., Lewis V.A., Macphee C.H., Milliner K.J., Moores K.E., Pinto I.L., Smith S.A., Stansfield I.G., Stanway S.J., Taylor M.A., Theobald C.J., Whittaker C.M. Bioorg. Med. Chem. Lett. 12:2002;2603. and references therein.
6. Bloomer J.C., Boyd H.F., Hickey D.M.B., Ife R.J., Leach C.A., Macphee C.H., Milliner K.J., Pinto I.L., Rawlings D.A., Smith S.A., Stansfield I.G., Stanway S.J., Taylor M.A., Theobald C.J., Whittaker C.M. Bioorg. Med. Chem. Lett. 11:2001;1925.
7. Ghosh C., Schmidt D.G., Pal B.C. J. Org. Chem. 49:1984;5257.
8. Boyd H.F., Fell S.C.M., Flynn S.T., Hickey D.M.B., Ife R.J., Leach C.A., Macphee C.H., Milliner K.J., Moores K.E., Pinto I.L., Porter R.A., Rawlings D.A., Smith S.A., Stansfield I.G., Tew D.G., Theobald C.J., Whittaker C.M. Bioorg. Med. Chem. Lett. 10:2000;2557.
9. Oral bioavailability was determined for the free base of 21 as described in ref 5, except that the iv infusion was in normal saline containing 10% (w/v) Encapsin and 2% (v/v) DMSO and the oral dose by gavage administration in 1% aq methylcellulose (rat) or by loose filled gelatine capsule (dog). The fed:fasted ratio in the rat was measured by oral gavage administration (10 mg/kg in 1% Tween 80 and 1% aq methylcellulose) to the conscious, cannulated fed or fasted male rat. Serial blood samples were collected up to 14 h post dose and analysed by LC/MS/MS. The fed:fasted ratio was calculated as AUC (fed)/AUC (fasted).
10. 2S requires 666.
11. Boyd H.F., Flynn S.F., Hickey D.M.B., Ife R.J., Jones M., Leach C.A., Macphee C.H., Milliner K.J., Rawlings D.A., Slingsby B.P., Smith S.A., Stansfield I.G., Tew D.G., Theobald C.J. Bioorg. Med. Chem. Lett. 10:2000;395.
12. Determined as in ref 5, data from 15 month old female WHHL rabbits. Compound 1 gave an inhibition of 74±9% in sex and age (14 months) matched WHHL rabbits.